Clinical Trials
Lundbeck initiates Lu AG09222 migraine prevention trial
Lu AG09222 mAb will inhibit PACAP, a neuropeptide implicated in migraine pathophysiology of migraine.
Lu AG09222 mAb will inhibit PACAP, a neuropeptide implicated in migraine pathophysiology of migraine.